18F-FES PET-CT Scan in Patients of Histopathologically Proven Estrogen Receptor Positive Breast Carcinoma at a Tertiary Care Facility

Sadia Adnan; Muhammad Numair Younis; Tahira Yasmin; Arzoo Fatima; Irfan Ullah Khan; Misbah Masood; Abubaker Shahid

doi:10.9734/jammr/2022/v34i631313

Submit Manuscript

Subscription

18F-FES PET-CT Scan in Patients of Histopathologically Proven Estrogen Receptor Positive Breast Carcinoma at a Tertiary Care Facility

Sadia Adnan

Muhammad Numair Younis

Tahira Yasmin

Arzoo Fatima

Irfan Ullah Khan

Misbah Masood

Abubaker Shahid

Journal of Advances in Medicine and Medical Research, Page 54-59
DOI: 10.9734/jammr/2022/v34i631313
Published: 1 April 2022

Abstract

Aims: To ascertain successful labeling and image performance of ¹⁸F-FES PET-CT scan in patients who have histopathologically diagnosed estrogen positive breast cancer.

Study Design: Histopathologically proven estrogen receptor positive patients were enrolled for ¹⁸F-FES PET-CT scan.

Place and Duration of Study: Department of Nuclear Medicine, Department of Radiopharmacy and Department of Oncology, Institute of Nuclear Medicine and Oncology Lahore- INMOL. Duration of the study including planning phase and performance of imaging was 6 weeks spanning between July till Aug 2021.

Methodology: ¹⁸F-FES was produced by direct nucleophilic radio-fluorination of 3-O-methoxymethyl-16,17 O sulfuryl-16-epiestriol followed by acidic hydrolysis at INMOL. After quality control tests, 18F-FES was injected to the patients. At 60 minutes post injection, each patient underwent PET-CT imaging in supine position as per standard protocol given in the published literature. Image interpretation and processing was performed.

Results: Study was performed on 2 patients. The first patient had estrogen receptor positive breast tumour on trucut biopsy and the second patient presented after excision biopsy. The second patient demonstrated skeletal, nodal and pulmonary metastases.¹⁸F-FES uptake was observed in the primary tumour as well as in all metastatic sites.

Conclusion: ¹⁸F-FES can successfully be labeled and ¹⁸-FES PET-CT can be performed in estrogen receptor positive breast cancer patients to take appropriate treatment decisions.

Keywords:

FES PET-CT
Breast Carcinoma
Estrogen receptors
Endocrine therapies

How to Cite

AdnanS., YounisM. N., YasminT., FatimaA., KhanI. U., MasoodM., & ShahidA. (2022). 18F-FES PET-CT Scan in Patients of Histopathologically Proven Estrogen Receptor Positive Breast Carcinoma at a Tertiary Care Facility. Journal of Advances in Medicine and Medical Research, 34(6), 54-59. https://doi.org/10.9734/jammr/2022/v34i631313

References

Krauss K, Stickeler E. Endocrine therapy in early BCa. Breast care (BASEL). 2020; 15(4):337-346. DOI: 10.1159/000509362. EPUB 2020 JUL 21. PMID: 32982643; PMCID: PMC7490651.

Eri Erik FJ, de Vries, Andor WJM. Glaudemans et al. PET-CT Beyond FDG: Hormonal Receptors PET-CT. Springer; 2010.

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G,. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary BCa and metastases. Eur J Cancer. 2014;50(2): 277-89. DOI: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21. PMID: 24269135.

Ashour F, Awwad MH, Sharawy HEL, Kamal M. Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in Cancer Stem Cells. J Egypt Natl Canc Inst. 2018; 30(2):45-48. DOI:10.1016/j.jnci.2018.04.002. Epub 2018 May 17. PMID: 29779937.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al; ESMO Guidelines Committee. Early BCa: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674. DOI: 10.1093/annonc/mdz189.

Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH et al. BCa, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452-478. DOI: 10.6004/jnccn.2020.0016. PMID: 32259783.

Miladinova D. Molecular Imaging in Breast Cancer. Nucl Med Mol Imaging. 2019; 53(5):313-319. DOI: 10.1007/s13139-019-00614-w. Epub 2019 Oct 16. PMID: 31723360; PMCID: PMC6821902.

Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, et al. Tissue confirmation of disease recurrencein patients with breast cancer: pooled analysis of two large prospective studies. Cancer Treat Rev. 2012;38:708–714. DOI: 10.1016/j.ctrv.2011.11.006 PMID: 22178456.

Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499–1504.
DOI:10.1093/annonc/mdp028
PMID: 19299408.

Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. J Nucl Med. 2021;62(3):326-331. DOI: 10.2967/jnumed.120.247882. Epub 2020 Jul.

Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist. 2020;25(10):835-844. DOI: 10.1634/theoncologist.2019-0967. Epub 2020 May 15. PMID: 32374053; PMCID: PMC7543360.

Boers J, Loudini N, Brunsch CL, Koza SA, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. J Nucl Med. 2021;62(9):1214-1220. DOI: 10.2967/jnumed.120.256826. Epub 2021 May 14. PMID: 33990400.

238 times
50 times

Download Statistics

Downloads

Download data is not yet available.